Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

Coronavirus disease 2019 (COVID‐19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID‐19 hyperimmune globulin (COVID‐HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP‐CorV (Sinopharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ding, Li, Yu‐Feng, Liang, Hong, Wu, Jun‐Zheng, Hu, Yong, Peng, Yan, Li, Tao‐Jing, Hou, Ji‐Feng, Huang, Wei‐Jin, Guan, Li‐Dong, Han, Ren, Xing, Yan‐Tao, Zhang, Yong, Liu, Jia, Feng, Lu, Li, Chun‐Yan, Liang, Xiao‐Long, Ding, Ya‐Ling, Zhou, Zhi‐Jun, Ji, De‐Ming, Wang, Fei‐Fei, Yu, Jian‐Hong, Deng, Kun, Xia, Dong‐Mei, Dong, De‐Mei, Hu, Heng‐Rui, Liu, Ya‐Jie, Fu, Dao‐Xing, He, Yan‐Lin, Zhou, Dong‐Bo, Yang, Hui‐Chuan, Jia, Rui, Ke, Chang‐Wen, Du, Tao, Xie, Yong, Zhou, Rong, Li, Ce‐Sheng, Wang, Man‐Li, Yang, Xiao‐Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108634/
https://www.ncbi.nlm.nih.gov/pubmed/35403837
http://dx.doi.org/10.1002/advs.202104333

Ejemplares similares

Ejemplares similares